Cargando…

VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo

Von Hippel-Lindau (VHL) disease is caused by germline mutations in the VHL tumor suppressor gene, with Type 2B missense VHL mutations predisposing to renal cell carcinoma, hemangioblastoma, and pheochromocytoma. Type 2B mutant pVHL is predicted to be defective in hypoxia inducible factor (HIF)-α reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, C M, Hickey, M, Sanford, C A, McGuire, C G, Cowey, C L, Simon, M C, Rathmell, W K
Formato: Texto
Lenguaje:English
Publicado: 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667565/
https://www.ncbi.nlm.nih.gov/pubmed/19252526
http://dx.doi.org/10.1038/onc.2009.12
_version_ 1782166147387359232
author Lee, C M
Hickey, M
Sanford, C A
McGuire, C G
Cowey, C L
Simon, M C
Rathmell, W K
author_facet Lee, C M
Hickey, M
Sanford, C A
McGuire, C G
Cowey, C L
Simon, M C
Rathmell, W K
author_sort Lee, C M
collection PubMed
description Von Hippel-Lindau (VHL) disease is caused by germline mutations in the VHL tumor suppressor gene, with Type 2B missense VHL mutations predisposing to renal cell carcinoma, hemangioblastoma, and pheochromocytoma. Type 2B mutant pVHL is predicted to be defective in hypoxia inducible factor (HIF)-α regulation. Murine embryonic stem (ES) cells in which the endogenous wild-type Vhl gene was replaced with the representative Type 2B VHL hotspot mutation R167Q (Vhl(2B/2B)) displayed preserved physiologic regulation of both HIF factors with slightly more normoxic dysregulation of HIF-2α. Differentiated Vhl(2B/2B)-derived teratomas over-expressed the joint HIF targets Vegf and EglN3 but not the HIF-1α-specific target Pfk1 and displayed a growth advantage over Vhl(-/-)-derived teratomas, suggestive of a tight connection between perturbations in the degree and ratio of HIF-1α and HIF-2α stabilization and cell growth. Vhl(2B/2B) mice displayed mid-gestational embryonic lethality, while adult Vhl(2B/+) mice exhibited susceptibility to carcinogen-promoted renal neoplasia compared with wild-type littermates at twelve months. Our experiments support a model in which the representative Type 2B R167Q mutant pVhl produces a unique profile of HIF dysregulation, thereby promoting tissue-specific effects on cell growth, development, and tumor predisposition.
format Text
id pubmed-2667565
institution National Center for Biotechnology Information
language English
publishDate 2009
record_format MEDLINE/PubMed
spelling pubmed-26675652009-10-09 VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo Lee, C M Hickey, M Sanford, C A McGuire, C G Cowey, C L Simon, M C Rathmell, W K Oncogene Article Von Hippel-Lindau (VHL) disease is caused by germline mutations in the VHL tumor suppressor gene, with Type 2B missense VHL mutations predisposing to renal cell carcinoma, hemangioblastoma, and pheochromocytoma. Type 2B mutant pVHL is predicted to be defective in hypoxia inducible factor (HIF)-α regulation. Murine embryonic stem (ES) cells in which the endogenous wild-type Vhl gene was replaced with the representative Type 2B VHL hotspot mutation R167Q (Vhl(2B/2B)) displayed preserved physiologic regulation of both HIF factors with slightly more normoxic dysregulation of HIF-2α. Differentiated Vhl(2B/2B)-derived teratomas over-expressed the joint HIF targets Vegf and EglN3 but not the HIF-1α-specific target Pfk1 and displayed a growth advantage over Vhl(-/-)-derived teratomas, suggestive of a tight connection between perturbations in the degree and ratio of HIF-1α and HIF-2α stabilization and cell growth. Vhl(2B/2B) mice displayed mid-gestational embryonic lethality, while adult Vhl(2B/+) mice exhibited susceptibility to carcinogen-promoted renal neoplasia compared with wild-type littermates at twelve months. Our experiments support a model in which the representative Type 2B R167Q mutant pVhl produces a unique profile of HIF dysregulation, thereby promoting tissue-specific effects on cell growth, development, and tumor predisposition. 2009-03-02 2009-04-09 /pmc/articles/PMC2667565/ /pubmed/19252526 http://dx.doi.org/10.1038/onc.2009.12 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Lee, C M
Hickey, M
Sanford, C A
McGuire, C G
Cowey, C L
Simon, M C
Rathmell, W K
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo
title VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo
title_full VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo
title_fullStr VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo
title_full_unstemmed VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo
title_short VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo
title_sort vhl type 2b gene mutation moderates hif dosage in vitro and in vivo
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667565/
https://www.ncbi.nlm.nih.gov/pubmed/19252526
http://dx.doi.org/10.1038/onc.2009.12
work_keys_str_mv AT leecm vhltype2bgenemutationmoderateshifdosageinvitroandinvivo
AT hickeym vhltype2bgenemutationmoderateshifdosageinvitroandinvivo
AT sanfordca vhltype2bgenemutationmoderateshifdosageinvitroandinvivo
AT mcguirecg vhltype2bgenemutationmoderateshifdosageinvitroandinvivo
AT coweycl vhltype2bgenemutationmoderateshifdosageinvitroandinvivo
AT simonmc vhltype2bgenemutationmoderateshifdosageinvitroandinvivo
AT rathmellwk vhltype2bgenemutationmoderateshifdosageinvitroandinvivo